Head-To-Head Analysis: Boston Scientific (NYSE:BSX) vs. Avivagen (OTCMKTS:VIVXF)

Boston Scientific (NYSE:BSX) and Avivagen (OTCMKTS:VIVXF) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

89.1% of Boston Scientific shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 2.1% of Avivagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Boston Scientific and Avivagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
Avivagen	N/A	N/A	N/A

Valuation & Earnings

This table compares Boston Scientific and Avivagen”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07 billion	3.57	$2.90 billion	$2.39	20.17
Avivagen	N/A	N/A	N/A	($0.04)	N/A

Boston Scientific has higher revenue and earnings than Avivagen. Avivagen is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Boston Scientific and Avivagen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	1	5	22	1	2.79
Avivagen	0	0	0	0	0.00

Boston Scientific currently has a consensus target price of $85.92, indicating a potential upside of 78.27%. Given Boston Scientific’s stronger consensus rating and higher probable upside, equities analysts plainly believe Boston Scientific is more favorable than Avivagen.

Summary

Boston Scientific beats Avivagen on 10 of the 11 factors compared between the two stocks.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

About Avivagen

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.